Effectiveness of Elobixibat and Linaclotide in neurogenic bowel dysfunction due to spinal cord injury

Effectiveness of Elobixibat and Linaclotide in neurogenic bowel dysfunction due to spinal cord injury - Effectiveness of Elobixibat and Linaclotide in neurogenic bowel dysfunction due to spinal cord injury

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000035923

Enrollment

Registered

2019-02-18

Start date

2019-02-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neurogenic bowel dysfunction due to spinal cord injury

Interventions

After a baseline period of two weeks, Elobixibat 10 mg is received once daily before breakfast during a treatment period of four weeks. If any side effect occurs, the dose is reduced to half. If th

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inpatients who are 18 years-old or older and have spinal cord injury with constipation, consenting for this study participation.

Exclusion criteria

Exclusion criteria: 1. Prohibited to use new laxatives 2. Having organic constipation 3. Having no problem of defecation 4. Time since injury is less than a month. 5. Having obvious problems of cognitive function 6. Having any severe health problem 7.Judged as ineligible for this study

Design outcomes

Primary

Measure	Time frame
Neurogenic Bowel Dysfunction score (NBD score) MOS 36-Item Short-Form Health Survey (SF-36) (the 2nd week in an observation period and the 1st/2nd/4th weeks after administration of new agents)	—

Countries

Japan

Contacts

Public ContactKyohei Matsuda

National Hospital Organization Murayama Medical Center Rehabilitation Medicine

k.matsuda0112@gmail.com042-561-1221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026